Andrew K. P. Taggart

发表

Role of GPR81 in lactate-mediated reduction of adipose lipolysis.

S. Kash, S. Wright, T. Cai, 2008, Biochemical and biophysical research communications.

(d)-β-Hydroxybutyrate Inhibits Adipocyte Lipolysis via the Nicotinic Acid Receptor PUMA-G*

D. Connolly, S. Offermanns, S. Wright, 2005, Journal of Biological Chemistry.

Tetrahydro anthranilic acid as a surrogate for anthranilic acid: application to the discovery of potent niacin receptor agonists.

Hong C Shen, J. Tata, S. Colletti, 2008, Bioorganic & medicinal chemistry letters.

Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression

D. Rader, D. Connolly, Jiajun Liu, 2012, Science Translational Medicine.

Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.

Hong C Shen, X. Tong, Qing Chen, 2010, Bioorganic & medicinal chemistry letters.

Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a).

J. Knudsen, C. Sage, E. Carballo-Jane, 2010, Bioorganic & medicinal chemistry letters.

Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G) Published, JLR Papers in Press, January 9, 2009.

S. Wright, T. Cai, Melba Hernandez, 2009, Journal of Lipid Research.

Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A.

Hong C Shen, J. Tata, S. Colletti, 2008, Bioorganic & medicinal chemistry letters.

Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A.

Kenneth K. Wu, Q. Deng, Hong C Shen, 2007, Bioorganic & medicinal chemistry letters.

(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans.

D. Connolly, J. Knudsen, C. Sage, 2012, Journal of medicinal chemistry.

Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia.

D. Blom, J. Tata, S. Colletti, 2009, Bioorganic & medicinal chemistry letters.

Identification of DGAT2 Inhibitors Using Mass Spectrometry

Shirly Pinto, D. McLaren, M. Garcia-Calvo, 2016, Journal of biomolecular screening.

Discovery and Pharmacology of a Novel Class of Diacylglycerol Acyltransferase 2 Inhibitors.

Shirly Pinto, D. McLaren, Sheng-ping Wang, 2015, Journal of medicinal chemistry.

Discovery of a brain-sparing GIRK1/4 inhibitor for pharmacological cardioversion of atrial fibrillation.

S. Peukert, Fupeng Ma, Yunshan Peng, 2023, Bioorganic & medicinal chemistry letters.

GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a.

J. Tata, S. Colletti, E. Carballo-Jane, 2010, Bioorganic & medicinal chemistry letters.

Anthranilic acid replacements in a niacin receptor agonist.

D. Blom, Hong C Shen, J. Tata, 2010, Bioorganic & medicinal chemistry letters.

Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.

M. Forrest, Kenneth K. Wu, Q. Deng, 2010, Journal of medicinal chemistry.

Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.

Kenneth K. Wu, Q. Deng, Hong C Shen, 2009, Journal of medicinal chemistry.

GPR109a agonists. Part 1: 5-Alkyl and 5-aryl-pyrazole-tetrazoles as agonists of the human orphan G-protein coupled receptor GPR109a.

J. Tata, S. Colletti, E. Carballo-Jane, 2009, Bioorganic & medicinal chemistry letters.

3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice.

D. Connolly, S. Tamura, C. Sage, 2008, Journal of medicinal chemistry.

Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.

M. Forrest, Kenneth K. Wu, Q. Deng, 2007, Journal of medicinal chemistry.

The use of stable-isotopically labeled oleic acid to interrogate lipid assembly in vivo: assessing pharmacological effects in preclinical species

D. Johns, Shirly Pinto, R. DeVita, 2011, Journal of Lipid Research.

Lack of authentic atrial fibrillation in commonly used murine atrial fibrillation models

S. Coughlin, Weiyan Li, O. Tarnavski, 2021, bioRxiv.

Molecular modeling aided design of nicotinic acid receptor GPR109A agonists.

Ning Ren, Q. Deng, Steven L Colletti, 2008, Bioorganic & medicinal chemistry letters.

The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME properties.

J. Tata, S. Colletti, J. Imbriglio, 2011, Bioorganic & medicinal chemistry letters.

Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists.

M. Forrest, M. E. Mccann, J. Tata, 2007, Journal of pharmacological and toxicological methods.

The design and implementation of a generic lipopeptide scanning platform to enable the identification of 'locally acting' agonists for the apelin receptor.

F. Zécri, E. Fortier, S. Pin, 2014, Bioorganic & medicinal chemistry letters.

Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression

D. Rader, D. Connolly, Jiajun Liu, 2012, Science Translational Medicine.

Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.

Hong C Shen, X. Tong, Qing Chen, 2010, Bioorganic & medicinal chemistry letters.